Research Grade Atacicept

Description: Atacicept (BS11217) is a research-grade recombinant antibody targeting CD256. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species:
Isotype: Fusion-[TNFRSF13B(tumornecrosisfactorreceptor(TNFR)superfamilymember13B,TACI,transmembraneactivatorandCAMLInteractor)]2-IGHG1Fc(Fragmentconstant)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: TNF-andAPOL-relatedleukocyteexpressedligand2,APRIL,CD256,Tumornecrosisfactorligandsuperfamilymember13,TNF-relateddeathligand1,TALL-2,TNFSF13,ZTNF2,Aproliferation-inducingligand,TALL2,TRDL-1,BAFF,ZTNF4,BLYS,Tumornecrosisfactorligandsuperfamilymember13B,Dendriticcell-derivedTNF-likemolecule,TALL-1,TNF-andAPOL-relatedleukocyteexpressedligand1,BLyS,Blymphocytestimulator,TNFSF13B,CD257,TNFSF20,TALL1,B-cell-activatingfactor
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: TACI-Fc,TACI-Ig,CAS:845264-92-8
Background: Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases.
Note: For research use only. Not suitable for clinical or therapeutic use.